129 related articles for article (PubMed ID: 18006783)
1. Gene expression analysis proposes alternative pathways for the mechanism by which celecoxib selectively inhibits the growth of transformed but not normal enterocytes.
Sagiv E; Rozovski U; Kazanov D; Liberman E; Arber N
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6807-15. PubMed ID: 18006783
[TBL] [Abstract][Full Text] [Related]
2. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells.
Lev-Ari S; Strier L; Kazanov D; Madar-Shapiro L; Dvory-Sobol H; Pinchuk I; Marian B; Lichtenberg D; Arber N
Clin Cancer Res; 2005 Sep; 11(18):6738-44. PubMed ID: 16166455
[TBL] [Abstract][Full Text] [Related]
3. Celecoxib leads to G2/M arrest by induction of p21 and down-regulation of cyclin B1 expression in a p53-independent manner.
Dvory-Sobol H; Cohen-Noyman E; Kazanov D; Figer A; Birkenfeld S; Madar-Shapiro L; Benamouzig R; Arber N
Eur J Cancer; 2006 Feb; 42(3):422-6. PubMed ID: 16426843
[TBL] [Abstract][Full Text] [Related]
4. Altered gene expression profiles define pathways in colorectal cancer cell lines affected by celecoxib.
Fatima N; Yi M; Ajaz S; Stephens RM; Stauffer S; Greenwald P; Munroe DJ; Ali IU
Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3051-61. PubMed ID: 18957522
[TBL] [Abstract][Full Text] [Related]
5. Gene expression following exposure to celecoxib in humans: pathways of inflammation and carcinogenesis are activated in tumors but not normal tissues.
Sagiv E; Sheffer M; Kazanov D; Shapira S; Naumov I; Kraus S; Domany E; Arber N
Digestion; 2011; 84(3):169-84. PubMed ID: 21546775
[TBL] [Abstract][Full Text] [Related]
6. Increased expression of cyclin D1 and the Rb tumor suppressor gene in c-K-ras transformed rat enterocytes.
Arber N; Sutter T; Miyake M; Kahn SM; Venkatraj VS; Sobrino A; Warburton D; Holt PR; Weinstein IB
Oncogene; 1996 May; 12(9):1903-8. PubMed ID: 8649851
[TBL] [Abstract][Full Text] [Related]
7. Celecoxib but not rofecoxib inhibits the growth of transformed cells in vitro.
Kazanov D; Dvory-Sobol H; Pick M; Liberman E; Strier L; Choen-Noyman E; Deutsch V; Kunik T; Arber N
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):267-71. PubMed ID: 14734479
[TBL] [Abstract][Full Text] [Related]
8. Malignant transformation of normal enterocytes following downregulation of Bak expression.
Liberman E; Naumov I; Kazanov D; Dvory-Sobol H; Sagiv E; Birkenfeld S; Deutsch V; Trakhtenbrot L; Moshkowitz M; Arber N
Digestion; 2008; 77(1):48-56. PubMed ID: 18349538
[TBL] [Abstract][Full Text] [Related]
9. D-Serine exposure resulted in gene expression changes indicative of activation of fibrogenic pathways and down-regulation of energy metabolism and oxidative stress response.
Soto A; DelRaso NJ; Schlager JJ; Chan VT
Toxicology; 2008 Jan; 243(1-2):177-92. PubMed ID: 18061331
[TBL] [Abstract][Full Text] [Related]
10. Up-regulation of p53 and mitochondrial signaling pathway in apoptosis by a combination of COX-2 inhibitor, Celecoxib and Dolastatin 15, a marine mollusk linear peptide in experimental colon carcinogenesis.
Piplani H; Vaish V; Rana C; Sanyal SN
Mol Carcinog; 2013 Nov; 52(11):845-58. PubMed ID: 22623379
[TBL] [Abstract][Full Text] [Related]
11. Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence.
Narayanan BA; Reddy BS; Bosland MC; Nargi D; Horton L; Randolph C; Narayanan NK
Clin Cancer Res; 2007 Oct; 13(19):5965-73. PubMed ID: 17908994
[TBL] [Abstract][Full Text] [Related]
12. Chronic treatment with celecoxib reverses chronic unpredictable stress-induced depressive-like behavior via reducing cyclooxygenase-2 expression in rat brain.
Guo JY; Li CY; Ruan YP; Sun M; Qi XL; Zhao BS; Luo F
Eur J Pharmacol; 2009 Jun; 612(1-3):54-60. PubMed ID: 19356723
[TBL] [Abstract][Full Text] [Related]
13. Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib.
Xie H; Gao L; Chai N; Song J; Wang J; Song Z; Chen C; Pan Y; Zhao L; Sun S; Wu K; Feitelson MA; Liu J; Fan D
Mol Carcinog; 2009 Jan; 48(1):56-65. PubMed ID: 18506760
[TBL] [Abstract][Full Text] [Related]
14. CD24 is a new oncogene, early at the multistep process of colorectal cancer carcinogenesis.
Sagiv E; Memeo L; Karin A; Kazanov D; Jacob-Hirsch J; Mansukhani M; Rechavi G; Hibshoosh H; Arber N
Gastroenterology; 2006 Aug; 131(2):630-9. PubMed ID: 16890615
[TBL] [Abstract][Full Text] [Related]
15. Effects of a selective cyclooxygenase-2 inhibitor on endometrial epithelial cells from patients with endometriosis.
Olivares C; Bilotas M; Buquet R; Borghi M; Sueldo C; Tesone M; Meresman G
Hum Reprod; 2008 Dec; 23(12):2701-8. PubMed ID: 18716040
[TBL] [Abstract][Full Text] [Related]
16. The anti-proliferative potency of celecoxib is not a class effect of coxibs.
Schiffmann S; Maier TJ; Wobst I; Janssen A; Corban-Wilhelm H; Angioni C; Geisslinger G; Grösch S
Biochem Pharmacol; 2008 Jul; 76(2):179-87. PubMed ID: 18547544
[TBL] [Abstract][Full Text] [Related]
17. Novel nitro-oxy derivatives of celecoxib for the regulation of colon cancer cell growth.
Bozzo F; Bassignana A; Lazzarato L; Boschi D; Gasco A; Bocca C; Miglietta A
Chem Biol Interact; 2009 Dec; 182(2-3):183-90. PubMed ID: 19682443
[TBL] [Abstract][Full Text] [Related]
18. Pilot randomized phase II study of celecoxib in oral premalignant lesions.
Papadimitrakopoulou VA; William WN; Dannenberg AJ; Lippman SM; Lee JJ; Ondrey FG; Peterson DE; Feng L; Atwell A; El-Naggar AK; Nathan CO; Helman JI; Du B; Yueh B; Boyle JO
Clin Cancer Res; 2008 Apr; 14(7):2095-101. PubMed ID: 18381950
[TBL] [Abstract][Full Text] [Related]
19. Celecoxib potentiates the anticancer effect of cisplatin on vulvar cancer cells independently of cyclooxygenase.
Kim SH; Kim SH; Song YC; Song YS
Ann N Y Acad Sci; 2009 Aug; 1171():635-41. PubMed ID: 19723114
[TBL] [Abstract][Full Text] [Related]
20. Microarray analysis of altered gene expression in murine fibroblasts transformed by nickel(II) to nickel(II)-resistant malignant phenotype.
Kowara R; Karaczyn A; Cheng RY; Salnikow K; Kasprzak KS
Toxicol Appl Pharmacol; 2005 May; 205(1):1-10. PubMed ID: 15885260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
